Developing a vaccine to prevent urogenital schistosomiasis
Antigen and adjuvant selection for a vaccine against urogenital schistosomiasis, Hematoshield
['FUNDING_OTHER'] · PAI LIFE SCIENCES, INC. · NIH-10818259
This study is testing a new vaccine to help prevent urogenital schistosomiasis, a disease caused by parasitic worms that can lead to serious health problems, and it's looking for participants to help see how well it works and if it's safe for different groups of people.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | PAI LIFE SCIENCES, INC. (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10818259 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a vaccine to combat urogenital schistosomiasis, a disease caused by parasitic worms that can lead to severe health issues, including bladder cancer. The team aims to leverage their previous work on a successful vaccine for a related parasite, using a specific antigen and an adjuvant to enhance the immune response. The research involves testing this new vaccine in clinical trials to ensure its safety and effectiveness in preventing infections. Patients may be involved in trials to assess the vaccine's performance and safety in diverse populations.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals living in regions where schistosomiasis is endemic, particularly women who may be at risk of infection.
Not a fit: Patients who are not at risk for schistosomiasis or those who have already been treated for the infection may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of urogenital schistosomiasis and its associated complications.
How similar studies have performed: Previous research has shown success with similar vaccine approaches for related schistosomiasis infections, indicating a promising avenue for this new vaccine.
Where this research is happening
SEATTLE, UNITED STATES
- PAI LIFE SCIENCES, INC. — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GRAY, SEAN ALEX — PAI LIFE SCIENCES, INC.
- Study coordinator: GRAY, SEAN ALEX
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immunodeficiency Syndrome Virus, Infection